U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H24N2O4
Molecular Weight 260.3304
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARISOPRODOL

SMILES

CCCC(C)(COC(=N)O)COC(=NC(C)C)O

InChI

InChIKey=OFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)

HIDE SMILES / InChI

Molecular Formula C12H24N2O4
Molecular Weight 260.3304
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including: http://www.ncbi.nlm.nih.gov/pubmed/22318620, http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c9184c0-7a2e-11df-8c8d-0002a5d5c51b

A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache. Carisoprodol might be mixtured with Aspirin and Codeine Phosphate. Studies indicating increased risk of abuse or addiction led to withdrawal of the drug from the market in Norway and other EU countries in 2008.

Originator

Curator's Comment:: Carisoprodol was developed in the 1950s by Dr. Frank M. Berger at Wallace laboratories on the basis of meprobamate.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
142.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SOMA

Approved Use

SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration

Launch Date

-3.38688016E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.2 μg/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.8 μg/mL
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
13.3 μM
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.5 μg × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7 μg × h/mL
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.7 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2 h
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
99 min
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
46%
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.5%)
Headache (0.5%)
Diarrhea (0.2%)
Stomach discomfort (0.2%)
Upper abdominal pain (0.2%)
Intervertebral disc protrusion (0.2%)
Pain in extremity (0.2%)
Abdominal distension (0.2%)
Sources: Page: 6
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.7%)
Headache (0.4%)
Stomach discomfort (0.7%)
Upper abdominal pain (0.7%)
Somnolence (0.7%)
Nausea (0.4%)
Rash (0.4%)
Nephrolithiasis (0.4%)
Intervertebral disc protrusion (0.4%)
Fatigue (0.4%)
Disorientation (0.4%)
Paraesthesia (0.4%)
Skin papilloma (0.4%)
Sources: Page: 6
2100 mg 1 times / day steady, oral
Highest studied dose
Dose: 2100 mg, 1 times / day
Route: oral
Route: steady
Dose: 2100 mg, 1 times / day
Sources:
unhealthy, adult
n = 9
Health Status: unhealthy
Age Group: adult
Sex: M
Population Size: 9
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal distension 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Diarrhea 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Intervertebral disc protrusion 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Pain in extremity 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Stomach discomfort 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Upper abdominal pain 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Dizziness 0.5%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Headache 0.5%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources: Page: 6
Disorientation 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Fatigue 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Headache 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Intervertebral disc protrusion 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Nausea 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Nephrolithiasis 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Paraesthesia 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Rash 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Skin papilloma 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Dizziness 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Somnolence 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Stomach discomfort 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Upper abdominal pain 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources: Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources: Page: 6
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
[Carisoprodol--one more time].
2002 Jan 30
Simultaneous determination of carisoprodol and acetaminophen in an attempted suicide by liquid chromatography-mass spectrometry with positive electrospray ionization.
2003 Mar
Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States.
2004 Dec 1
Impairment due to intake of carisoprodol.
2004 Jun 11
Human pharmaceuticals, hormones, and personal care product ingredients in runoff from agricultural fields irrigated with treated wastewater.
2005 Mar 9
Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
2005 Sep-Oct
Carisoprodol withdrawal induced delirium: A case study.
2007
Carisoprodol abuse in Mississippi.
2007 Dec
Upper limb impairments associated with spasticity in neurological disorders.
2007 Nov 29
Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003.
2007 Sep
Reliability of Ashworth and Modified Ashworth scales in children with spastic cerebral palsy.
2008 Apr 10
Double-blind, placebo-controlled trial of carisoprodol 250-mg tablets in the treatment of acute lower-back spasm.
2008 Feb
[Toxicological screening of medicines and drugs of abuse in emergency cases].
2008 Jan 3
[The Somadril Association in Norway].
2008 Jun 26
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.
2009
Reliability and validity of pendulum test measures of spasticity obtained with the Polhemus tracking system from patients with chronic stroke.
2009 Jul 30
[Prescription shopping of addictive drugs in Norway].
2009 Mar 12
Prescription pattern of codeine for non-malignant pain: a pharmacoepidemiological study from the Norwegian Prescription Database.
2009 May
Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.
2009 May
Fibromyalgia and myofascial pain syndrome-a dilemma.
2009 Oct
Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions.
2010
Carisoprodol legal status and patterns of abuse.
2010 Dec
Rapid and sensitive LC-MS/MS method for determination of felbamate in mouse plasma and tissues and human plasma.
2010 Dec 15
INCITE: A randomised trial comparing constraint induced movement therapy and bimanual training in children with congenital hemiplegia.
2010 Jan 12
Carisoprodol: abuse potential and withdrawal syndrome.
2010 Mar
Patents

Sample Use Guides

250 mg to 350 mg three times a day and at bedtime
Route of Administration: Oral
In Vitro Use Guide
HEK293 cells were transiently transfected with human alpha1beta2 and alpha1beta2gamma2 receptors. Whole-cell patch clamp electrophysiology was used to assess carisoprodol-activated Cl- current. EC50 value for carisoprodol was 142 ± 13 uM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:56:20 UTC 2021
Edited
by admin
on Fri Jun 25 20:56:20 UTC 2021
Record UNII
21925K482H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARISOPRODOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
(+/-)-2-METHYL-2-PROPYL-1,3-PROPANEDIOL CARBAMATE ISOPROPYLCARBAMATE
Systematic Name English
CARISOPRODOL [HSDB]
Common Name English
CARISOPRODOL COMPONENT OF CARISOPRODOL COMPOUND
Common Name English
CARISOPRODOL [USP MONOGRAPH]
Common Name English
CARISOPRODOL [EP]
Common Name English
NSC-172124
Code English
CARISOPRODOL [MI]
Common Name English
CARISOPRODOL [JAN]
Common Name English
CARISOPRODOL [INN]
Common Name English
SOMA
Brand Name English
RELA
Brand Name English
CARISOPRODOL CIV
USP-RS  
Common Name English
CARISOPRODOL COMPONENT OF SOMA COMPOUND
Common Name English
SOMA COMPOUND COMPONENT CARISOPRODOL
Common Name English
CARISOPRODOL [VANDF]
Common Name English
CARISOPRODOL [ORANGE BOOK]
Common Name English
CARISOPRODOL CIV [USP-RS]
Common Name English
CARISOPRODOL [WHO-DD]
Common Name English
CARISOPRODOL COMPOUND COMPONENT CARISOPRODOL
Common Name English
CARISOPRODOL [MART.]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175737
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
LIVERTOX 151
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
WHO-ATC M03BA72
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
WHO-VATC QM03BA72
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
WHO-VATC QM03BA52
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
WHO-ATC M03BA02
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
NCI_THESAURUS C29696
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
WHO-VATC QM03BA02
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
DEA NO. 8192
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
WHO-ATC M03BA52
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
NDF-RT N0000175730
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C28904
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
MESH
D002328
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
WIKIPEDIA
CARISOPRODOL
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
USP_CATALOG
1096600
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY USP-RS
LACTMED
Carisoprodol
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
FDA UNII
21925K482H
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
IUPHAR
7610
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
HSDB
3021
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
DRUG BANK
DB00395
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
EPA CompTox
78-44-4
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
PUBCHEM
2576
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
CAS
78-44-4
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
DRUG CENTRAL
509
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
EVMPD
SUB06631MIG
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
ECHA (EC/EINECS)
201-118-7
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
MERCK INDEX
M3112
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY Merck Index
RXCUI
2101
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY RxNorm
INN
902
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
ChEMBL
CHEMBL1233
Created by admin on Fri Jun 25 20:56:20 UTC 2021 , Edited by admin on Fri Jun 25 20:56:20 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC